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Abstract
Background: In a cross-sectional study we studied the fasting serum DPP-4 enzymatic activity (sDPP-4) and the insulin
resistance index (HOMA2-IR) in gliptin naı¨ve patients with type 2 diabetes and in non-alcoholic fatty liver disease (NAFLD)
and in healthy controls (CNTRL).
Methods and Findings: sDPP-4 was measured by kinetic assay in 39 NAFLD (F/M:19/20, mean age: 47.42 yrs) and 82 type 2
diabetes (F/M:48/34, 62.8 yrs) patients and 26 (F/M:14/12, 35.3 yrs) controls. Definition of T2D group as patients with type 2
diabetes but without clinically obvious liver disease created non-overlapping study groups. Diagnosis of NAFLD was based
on ultrasonography and the exclusion of other etiololgy. Patients in T2D and NAFLD groups were similarly obese. 75 g CH
OGTT in 39 NAFLD patients: 24-NGT, 4-IGT or IFG (‘‘prediabetes’’), 11-type 2 diabetes. HOMA2-IR: CNTRL: 1.44; T2D-group:
2.62 (p = 0.046 vs CNTRL, parametric tests); NAFLD(NGTonly): 3.23 (p = 0.0013 vs CNTRL); NAFLD(IFG/IGT/type 2 diabetes):
3.82 (p,0.001 vs CNTRL, p = 0.049 vs 2TD group). sDPP-4 activity was higher in NAFLD both with NGT (mean:33.08U/L) and
abnormal glucose metabolism (30.38U/L) than in CNTRL (25.89U/L, p,0.001 and p= 0.013) or in T2D groups (23.97U/L,
p,0.001 and p= 0.004). Correlations in NAFLD among sDPP-4 and ALT: r = 0.4637,p = 0.0038 and cGT: r = 0.4991,p = 0.0017
and HOMA2-IR: r = 0.5295,p = 0.0026 and among HOMA2-IR and ALT: r = 0.4340,p = 0.0147 and cGT: r = 0.4128,p = 0.0210.
Conclusions: The fasting serum DPP-4 activity was not increased in T2D provided that patients with liver disease were
intentionally excluded. The high serum DPP-4 activities in NAFLD were correlated with liver tests but not with the fasting
plasma glucose or HbA1C supporting that the excess is of hepatic origin and it might contribute to the speedup of
metabolic deterioration. The correlation among cGT, ALT and serum DPP-4 activity and also between serum DPP-4 activity
and HOMA2-IR in NAFLD strongly suggests that serum DPP-4 activity should be considered as a novel liver disease
biomarker.
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Introduction
Individuals with obesity had 4-fold risk and type 2
diabeticpatients do also have higher risk of dying from cirrhosis
than the general population .[1,2] Vica-versa in the Insulin
Resistance Atherosclerosis Study (IRAS) elevated ALT was
independently associated with insulin resistance and other
findings are also consistent with the role of liver fat in diabetes
pathogenesis.[3,4]
Dipeptidyl peptidase-4 (DPP-4) inactivates both incretin hor-
mones (GIP, GLP-1), therefore DPP-4 inhibitors are used in the
treatment of type 2 diabetes.[5] The prevalence of fatty liver
disease in a population based study was 34% over 90% of which
was due to non-alcoholic causes (NAFLD) that is generally
asymptomatic, frequently associated with obesity, type 2 diabetes
and metabolic syndrome.[6,7]
The link between the serum DPP-4 activity and different
chronic liver disease, such as the chronic C-virus hepatitis has been
previously well established. Higher serum DPP-4 activity was
found in patients with chronic C-virus hepatitis, which infectious
disease is well known to be associated with diabetes mellitus and
insulin resistance.[8,9] DPP-4 (identical to CD26) is detectable in
soluble form in the serum and DPP-4 is widely expressed in the
body including bile canaliculi, hepatocytes and hepatic stellate
cells (HSCs).[10,11]
Despite the clear epidemiological associations between the
metabolic disorders and chronic liver diseases the exact molecular
paths via these clinically important links evolve have not yet been
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fully elucidated. We first hypothesized that in NAFLD the DPP-4
enzymatic activity is increased which might contribute to the
development of type 2 diabetes and metabolic deterioration. The
fasting serum DPP-4 enzymatic activity (sDPP-4) was measured in
patients with NAFLD and in similarly obese patients with type 2
diabetes but without clinically evident liver disease (defined as
T2D group) and also in healthy controls (CNTRL).
Methods
Study design and patients
All 147 participants signed the informed consent and this cross-
sectional study was approved by the Semmelweis University
Regional and Institutional Committee of Science and Research
Ethics.
All 39 NAFLD pts were followed by hepatologist and had
elevated liver tests for more than 3 months and were diagnosed as
having fatty liver by ultrasonography.
All the other possible etiologies such as viral hepatitis, storage
diseases including Wilson disease, hemochromatosis and alpha-1
antitrypsin deficiency, autoimmune hepatitis, celiac disease, drug-
induced liver disease and rapid loss of weight were excluded. None
of these pts had alcohol related disease in the history and none of
them had alcohol intake more than 20 g/day. None of the patients
had a suggestive family history for a well defined hereditary
syndrome and none of the patients presented with seemingly
unrelated organ dysfunction.
Although only two out of 39 pts underwent liver biopsy that
confirmed the clinical diagnosis and showed macrovesicular
steatosis, we applied a non-invasive scoring system to evaluate
fibrosis [12] and OGTT (75 gCH) to assess carbohydrate
metabolism (except 9 patients with previously known diabetes) in
NAFLD. Routine clinical data (including waist circumference),
family history, clinical chemistry were recorded.
Separately, 82 type 2 diabetic individuals (23 on insulin therapy)
were enrolled from the diabetology outpatient unit, patients with
elevated liver tests within 12 months and/or abnormal liver
ultrasonography were not eligible for enrolment to this T2D
group. Twenty-six volunteers were healthy controls. Homeostasis
model assessment (HOMA2-IR) index was calculated using the
computer model (http://www.dtu.ox.ac.uk) due to the higher
accuracy compared to the HOMA1 method.[13] Metabolic
syndrome was both defined as proposed by the NCEP in ATP-
III and as recently suggested by the AHA and IDF.[14,15]
Clinical characteristics
Clinical data are indicated in table 1.
Determination of serum DPP-4 activity and other
biomarkers
Serum DPP-4 activities were assessed in 39 pts with NAFLD
in 82 pts with type 2 diabetes mellitus and in 26 healthy controls.
DPP IV activity was determined in a continuous monitoring
assay in a microplate reader (Multiskan Plus MK II, Labsystem)
at 405 nm, 25uC for 30 min under similar conditions as
described earlier.[8,16] All DPP IV assays were run in
duplicates. Fifteen ml serum and 185 ml assay buffer (10 mM
Tris-HCl, pH 7.6) containing 2 mmol/L substrate (Gly-Pro-p-
nitroanilide tosylate, Gly-Pro-PNA, Bachem, Bubendrof, Swit-
zerland) were pipetted into each microplate wells. Enzyme
activity was expressed in nmol/mL/min (U/L) of Gly-Pro-PNA
hydrolysed. Aspartate-aminotransferase (AST), alanin-amino-
transferase (ALT), gamma-glutamyl-transferase (cGT), alkaline
phosphatase (ALP) activities were determined in Olympus
AU2700 autoanalyser at 37uC. The enzyme activities are
expressed in U/L; bilirubin concentration is given in mmol/L.
The index of insulin resistance (IR) was calculated using the
HOMA-2 model after fasting insulin and plasma glucose
measurements. Specific insulin or C-peptide measurements were
made using the Liaison C-peptide and insulin tests on a Liaison
analyzer (DiaSorin, Saluggia, Italy).
Data analysis and statistics
The distribution of data was assessed by the Kolmogorov-
Smirnov test. Because we found normal distribution one-way
ANOVA with Scheffe’s and Newman-Keuls post hoc test and
Pearson correlation were used to compare means and asses
correlations, p-values lower than 0.05 were evaluated as significant.
Results
Clinical data
See in table 1.
Serum DPP-4 enzyme activity and HOMA2-IR
Fifteen patients out of 39 in the NAFLD group had abnormal
glucose metabolism: 11 NAFLD patients presented with type 2
diabetes mellitus and 4 NAFLD patients had (‘‘prediabetes’’) either
impaired fasting glucose levels or impaired glucose tolerance at the
OGTT (75 gCH).
In order to generate non-overlapping groups from the point of
diabetes we also analyzed separately the NAFLD patients with
normal and abnormal glucose metabolism:
Fasting serum DPP-4 activity was higher in NAFLD patients both
with NGT (mean:33.08U/L, 95%CI:30.47–35.69) and abnormal
glucose metabolism (mean:30.38U/L, 95%CI:27.08–33.68) than
in controls (25.89U/L,95%CI: 23.38–28.4, Newman-Kleus
p,0.001 and p = 0.013) or in the T2DM (&NAFLD clinically
excluded) group (23.97U/L,95%CI: 22.32–25.6 p,0.001 and
p = 0.004, respectively). (Figure 1).
An interesting step-by-step increase was observed in the
HOMA2-IR:
Controls: mean: 1.44 (95%CI: 1.05–1.85) - T2D-(NAFLD
excluded): 2.62 (95%CI: 2.22–3.01, p = 0.046 vs CNTRL) -
NAFLD with NGT only: 3.23 (95%CI:2.44–4.01, p = 0.0013 vs
CNTRL) and NAFLD with IFG/IGT/2TDM: 3.82 (95%CI:3.19–
4.44, p,0.0001 vs CNTRL, p = 0.049 vs 2TD group). (Figure 2).
Correlation among the serum DPP-4 activity, liver tests
and HOMA2-IR in NAFLD
Highly significant correlations were detected among the serum
DPP-4 activity and ALT (r = 0.4637 p = 0.0038) and cGT
(r = 0.4991, p = 0.0017) values in 39 patients with NAFLD. We
performed logarithmic transformation of the liver tests and correlated
the values with the logarithmically transformed serum DPP-4
activities (logALT vs logsDPP-4: r = 0.4087; p = 0.0120 and logcGT
vs logsDPP-4: r = 0.3827; p = 0.0194-figure 3 and figure 4) these
correlations were also significant in the NAFLD group. (Figure 3,
Figure 4) Direct correlation was also detected between the serum
DPP-4 activity and the HOMA2-IR (r = 0.5295, p = 0.0026) in
NAFLD patients. (Figure 5) Further significant correlation was found
between the serum DPP-4 activity and the ALP values in NAFLD
patients, however this was a magnitude less significant (r = 0.3379,
p = 0.0408) than the ones described above.
The HOMA2-IR values were also directly correlated with the
ALT (r = 0.4340, p = 0.0147) and cGT (r = 0.4128, p = 0.0210,)
but not with the AST or ALP in NAFLD patients. No further
correlation was found in this set of NAFLD patients. There was
sDPP4-NAFLD: Novel Liver Test
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neither correlation between the serum DPP-4 activity and the
HbA1C values nor between the DPP-4 activity and the fasting
plasma glucose in the T2D group.
Multiple Logistic Regression
Logistic regression was applied to create a formula employing 9
predictive factors (serum DPP-4, fasting plasma glucose, HOMA2-
IR, HbA1c, ALAT, ASAT, ASAT/ALAT, gGT, TG) that
separates patients in the NAFLD group from those in the T2D
group with 92.3% sensitivity and 86.7% specificity as indicated in
the ROCurve on Figure 6.
Multiple Logistic Regression Equation = 0.704920.023*(Fast-
ing Plasma Glucose)+0.0188*(HOMA2-IR)20.084*(HbA1c)+
0.0092*(sDPP24)+0.004*(ASAT)+0.0000072*(ALAT)+0.0004*
(gGT)20.2859*(ASAT/ALAT)+0.0819*(TG). (Criterion 0.3712,
below: T2D, above: NAFLD) In addition there was a trend
towards higher ALP levels reflected by the number of individuals
by ALP quartiles and above increasing form healthy individuals
through the T2D to the NAFLD groups.
Medications applied in the study
Although differences were recorded between the study groups in
the medication applied (Metformin, Statins, Glitazons: NAFLD:
12.8%, 35.9%, 2.6%; T2D: 68.3%, 45.1%, 2.4% respectively)
these are neither likely to have a major impact on the NAFLD
group due to the low rate of biguanid use nor could explain the
differences found between the groups due to the similar rate of
statin and glitazon use. No difference was found between the
metformin taking and non-taking patients in the T2D group in the
serum DPP-4 activity (Metformin non-taking: 25.98 U/L
(95%CI: 21.39–30.58) Metformin taking: 23.67 U/L (95%CI:
21.82–25.51).
Table 1. Clinical characteristics and the fasting serum DPP-4 activities of healthy individuals (CNTRL) and patients type with 2
diabetes mellitus (2TDM) and non-alcoholic fatty liver disease (NAFLD).
CNTRL 2TDM NAFLD*
No of pts (F/M) 26 (12/11) 82(48/34) 39 (19/20)
Age (y) 35.33 (28.76241.91) 62.8 (60.4265.1) 47.42 (43.83251)
BMI (kg/m2) 24.49 (22.25226.73) 29.77 (28.58230.96) 30.36 (29231.72)
Abdominal circumference (cm):
F/M
77.70(63.4292)/96.71
(84.422109)
107.6 (102.842112.34)/109.91
(104.232115.58)
103.73 (95.592111.88)/110.56
(105.922115.20)
Fasting Plasma Gglucose (mmol/L) 4.97 (4.7425.2) 8.2 (7.5128.87) 6.38 (5.926.87)
HbA1C (%) 5.46 (5.3325.58) 7.53 (7.1827.88) 5.79 (5.5426.03)
TG (mmol/L)*** 1.12 (0.8521.38) 1.94 (1.6822.2) 2.41 (1.9122.91)
LDL-C (mmol/L)**** 2.57 (1.9323.2) 2.99 (2.7623.22) 3.41 (3.0423.78)
ALT (U/L) 22.83 (17.40228.25) 21.75 (19.46224.03) 54.59 (38.49270.68)
AST (U/L) 26 (21.78230.24) 22.64 (20.7224.59) 35.13 (28.66241.59)
cGT (U/L) 23.09 (17.74228.43) 31.18 (28.22234.14) 100.23 (63.262137.2)
HOMA2-IR index 1.44 (1.0521.85) 2.62** (2.2223.01) 3.48 (2.9723.98)
Fasting Insulin** 14.9 (11.8218) 17.09** (13.79220.4) 20.42 (16.58224.27)
AST/ALT 1.18 (1.021.55) 1.15 (1.0521.25) 0.80 (0.7020.89)
Metabolic syndrome n/n(%)***** 0/26 (0%) NCEP
0/26 (0%)
68/82 (82.9%) NCEP
68/82 (82.9%)
21/39 (54%) NCEP
20/39 (51%)
Fasting serum DPP-4 (U/L) 25.89 (24.35227.43) 23.97 (22.32225.61) 32.15 (29.51234.80)
Mean values are indicated in bold letters and (95% Confidence Intervals are indicated in parenthesis).
*All NAFLD patients, except 9 previously known diabetic individuals underwent a 75g CH OGTT:
24 NAFLD patients were with normal glucose tolerance (NGT), 4 had either impaired fasting glucose levels or impaired glucose tolerance (‘‘prediabetes’’: IFG/IGT), and
11pateint from the NAFLD group were with type 2 diabetes mellitus (28%).
All patients in the 2TDM group were with normal liver tests and normal liver US morphology (patients with such abnormalities were either excluded from the study or
re-classified to the NAFLD group).
In order to generate non-overlapping groups from the point of diabetes we also analyzed separately the DPP-4 activity in patients with NGT and NAFLD that was (33.08
U/L (95%CI:29.66–36.50) significantly higher in comparison with the 2TDM and also compared to the healthy control group. (see figure 1).
In patients with NAFLD a non-invasive fibrosis score was used to assess the degree of intrahepatic fibrosis as suggested and validated by Angulo et al. (12) Results are as
follows:
No of pts without significant fibrosis (stage 0–2) (NAFLD fibrosis score,21.455): 29.1.
Indeterminate (NAFLD fibrosis score21.455–0.676): 6.
No of pts with significant fibrosis (stage 3–4) (NAFLD fibrosis score.0.676): 4.
**23 out of the 82 patients with type 2 diabetes mellitus were treated with insulin – in these cases the HOMA2-IR was calculated using the C-peptide levels.
***Significant differences were found in certain lipid values using ANOVA with the Newman-Kleus post hoc range test in the 39 patients with NAFLD as follows: NAFLD
patients also displayed higher triglyceride (TG) levels (2.41mmol/L, 95%CI:2.04–2.78) than in the CNTRL group (1.12mmol/L, 95%CI:0.65–1.58, p,0.001) and the TG levels
in the NAFLD group were non-significantly higher than in the T2DM group (1.94, 95%CI: 1.68–2.2).
****The LDL-cholesterol was significantly elevated in NAFLD (3.41mmol/L, 95%CI: 3.05–3.77) compared to controls (2.66mol/L, 95%CI: 2.19–3.13, p = 0.012). The HDL
cholesterol was significantly lower in both the T2D group (1.30mmol/L, 95%CI: 1.21–1.39, p,0.05) and the NAFLD group (1.28, 95%CI: 1.15–1.40, p = 0.02) then in the
healthy controls (1.54, 95%CI: 1.36–1.69).
*****Metabolic syndrome was both defined as proposed by the NCEP in ATP-III (indicated as NCEP in the table) and as recently suggested by the AHA and IDF the
proportion in each study group was calculated using both methods respectively (14, 15).
doi:10.1371/journal.pone.0012226.t001
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Discussion
In this cross-sectional study fasting serum dipeptidyl peptidase 4
activity and insulin resistance were assessed in two selected groups
of patients, one with non-alcoholic fatty liver disease and the other
with type 2 diabetes mellitus without clinically evident liver disease
and all results were compared to that of healthy controls (table 1).
DPP-4 inhibitor (Gliptin) naı¨ve diabetic patients were subjected to
scrutiny due to the success of DPP-4 inhibitors in the treatment of
type 2 diabetes mellitus that leads to improved glycemic control by
stimulating insulin secretion and biosynthesis, B-cell proliferation
and by inhibiting glucagon release and B-cell apoptosis. [5]
Figure 1. Fasting serum DPP-4 enzymatic activities in patients with type 2 diabetes without clinically diagnosed liver disease (2TD
group); in NAFLD patients with normal and abnormal glucose metabolism and in healthy controls (CNTRL group).
doi:10.1371/journal.pone.0012226.g001
Figure 2. HOMA2-Insulin resistance index in patients with type 2 diabetes without clinically diagnosed liver disease (2TD group), in
NAFLD patients with normal and abnormal glucose metabolism and in healthy controls (CNTRL group).
doi:10.1371/journal.pone.0012226.g002
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Despite the large number of clinical trials relatively low number of
data were available on the serum DPP-4 enzyme activity prior the
initiation of inhibitor therapy. [17,18] In addition that NAFLD is
frequently associated with type 2 diabetes, obesity and the
metabolic syndrome higher serum DPP-4 activities were reported
in chronic liver diseases with other origin. [8,9] We presumed that
in patients with NAFLD the serum DPP-4 activity would be
increased and -via the dysfunctional enetro-insular axis- it might
contribute to the impairment of glucose tolerance and the speedup
of metabolic deterioration observed in NAFLD. [3]
Surprisingly serum DPP-4 activity was not increased in the T2D
group provided that patients with clinically obvious liver disease
were intentionally excluded from this study group. In addition we
could neither confirm the correlation between sDPP-4 and
HbA1C values nor between sDPP-4 and fasting plasma glucose
that were reported earlier in type 2 diabetes with smaller sample
sizes. [16,17] Thus, we think that the increment of serum DPP-4
activity reported earlier in patients with type 2 diabetes by others
might also be due to the uncounted or unrecognized liver disease.
[16,17]
Conversely the sDPP-4 showed correlation with liver tests (ALT,
cGT, and less significantly ALP) in NAFLD (Figure 3, 4), such as
in previous reports on chronic liver diseases with different
aetiology. [8,9] Therefore the single publication with lower
number of non-alcoholic steatohepatitis patients the serum DPP-
4 activity is likely to be influenced by a fundamental bias due to the
Figure 3. Significant correlation (r = 0.4087; p = 0.0120) between the liver disease biomarker ALT and the fasting serum DPP-4
enzymatic activity after logarithmic transformation in NAFLD patients.
doi:10.1371/journal.pone.0012226.g003
Figure 4. Significant correlation (r = 0.3827; p = 0.019) between the liver disease biomarker cGT and the fasting serum DPP-4
enzymatic activity after logarithmic transformation in NAFLD patients.
doi:10.1371/journal.pone.0012226.g004
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lack of correlations between the serum DPP-4 activity and liver
tests.[18]
The positive correlation found among cGT, ALT and serum
DPP-4 activities in NAFLD supports that the excess DPP-4 found
in the serum is of hepatic origin (Figure 3, 4). When we analyzed
two NAFLD subgroups separately (with normal and abnormal
glucose metabolism, respectively) and compared the sDPP-4 to
that of the CNTRL and T2D groups (in which liver disease was
clinically excluded) we concluded that it is the presence of the
(fatty) liver disease that has a primary impact on the serum DPP-4
enzymatic activity and not the hyperglycemia alone. (Figure 1)
Vica versa - a significant role of DPP-4 in the hepatic glucose
metabolism is further supported by the recent study of Edgerton et
al. demonstrating that during vildagliptin and GLP-1 co-treatment
the net hepatic glucose uptake was 3-fold greater in the DPP-4
inhibitor treated group than in the control group that was only
treated with portal vein GLP-1 infusion but not with the DPP-4
inhibitor and this effect was greater than that predicted by the
change in insulin. In this phenomenon the glucagon-lowering
effect of DPP-4 vildagliptin must also be taken into consideration
[19] In addition this increased serum DPP-4 activity in NAFLD
could not be explained by the degree of obesity and (Table 1) the
existing correlation between serum DPP-4 activity and insulin
resistance (HOMA2-IR) in NAFLD is not surprising, provided
that serum DPP-4 activity is considered as a novel liver disease
biomarker. (Figure 5)
As published recently by Tabak et al [20] using HOMA method
the insulin sensitivity starts to decline earlier (based on his figures-
approximately 4 years before the diabetes onset) throughout the
course in the development of type2 diabetes mellitus than the
definitive impairment of the glucose tolerance. In addition HOMA
mostly describes hepatic insulin resistance and steady-state insulin
secretion due to the calculation from the fasting plasma glucose
and insulin values. Nevertheless the HOMA2-IR calculation might
reflect an underestimation of insulin resistance in the T2D group
due to the fact that majority of our patients was on metformin
therapy and due to the calculation method in this study group.
Taken this information together with our observation that NAFLD
patients with normal glucose tolerance have similar HOMA2-IR
values than those with type 2 diabetes, but without liver disease we
would rather interpret this phenomenon as a balanced insulin
resistant state, in which the higher insulin secretion and better Beta
cell function in NAFLD patients overcomes the already increased
insulin resistance compared to the T2D group where a significant
B-cell dysfunction could be detected. To prove this explanation we
have compared HOMA-B values of NAFLD patients to that of the
Figure 5. Significant correlation (r = 0.5295; p = 0.0026) between the HOMA2-Insulin resistance index and the fasting serum DPP-4
enzymatic activity in NAFLD patients.
doi:10.1371/journal.pone.0012226.g005
Figure 6. ROCurve for Multiple Logistic Regression (Equation
= 0.704920.023*(Fasting Plasma Glucose)+0.0188*(HOMA2-
I R )20 . 0 8 4 * ( H b A 1 c )+0 . 0 0 9 2 * ( s D P P24 )+0 . 0 0 4 * ( A S A -
T )+0 . 0 0 0 0 0 7 2 * ( A L A T )+0 . 0 0 0 4 * ( g G T )20 . 2 8 5 9 * ( A S A T /
ALAT)+0.0819*(TG). Criterion 0.3712, below: T2D, above:
NAFLD).
doi:10.1371/journal.pone.0012226.g006
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T2D group and found significantly higher values (NAFLD:
127.3%649.5 vs T2D: 67.8%6SD40.9 p,0.0001, two tailed T-
test). Our cross sectional study might not directly explore the order
of events leading to the development of type 2 diabetes mellitus
due to the lack of a follow-up period.
Although the membrane bound form of DPP-4 which prepon-
derantly degrades incretin hormones in a local action could not
have been assessed in our study, the serum DPP-4 enzymatic
activity might be responsible up to 15% of the incretin hormone
inactivation process. [5,21] We must also mention that healthy
volunteers were not appropriately age matched controls for type 2
diabetic patients, therefore the influence of ageing on the serum
DPP-4 enzyme activity should also be taken into consideration.
The step-by-step increase observed in the HOMA2-IR (Figure 2)
with a sequence of.
Healthy controls , T2DM-(if NAFLD excluded) , NAFLD
with NGT only , uttermost in NAFLD patients who also
presented with abnormal glucose metabolism raises a number of
pathophysiological questions. In patients with obesity and 2TDM
but without clinically diagnosed liver disease the deterioration of
carbohydrate metabolism especially in comparison with the
subgroup of NAFLD patients with normal glucose tolerance, but
with higher HOMA2-IR values might not only be due to the
higher insulin resistance (compared to healthy individuals) but also
due to the likely B-cell dysfunction.
Although a statement was published recently for harmonizing
the various definitions for the metabolic syndrome [15], in this
study 49% of NAFLD patients did not fulfil this criteria of the
metabolic syndrome, despite that their HOMA2-IR values were
even higher than those with type 2 diabetes but without clinically
diagnosed liver disease. Therefore we concluded that even this
novel definition might not be evaluated as a perfect harmony since
a significant proportion of insulin-resistant patients missed the
criteria. In harmony with the data presented here in the IRAS
study involving a large cohort, the authors also concluded that the
ALT, another liver disease biomarker was independently associ-
ated with insulin resistance.[3] These findings are in concordance
with the British Women’s Heart and Health Study that observed
more than a doubling in the risk of incident diabetes in
ultrasonography-diagnosed NAFLD and also with the recent
French data from the DESIR study that proved that individuals
with a BMI of ,27 kg/m2 gGT is the strongest predictor of
diabetes after fasting hyperglycemia. [4,22]
Based on these results, DPP-4 inhibitors might offer an
alternative in the potential prevention of further metabolic
deterioration, especially in NAFLD patients. In addition to the
potential metabolic benefits, the impact of such therapy on the
liver fibrosis might also be in the focus of interest especially
because the Fibroblast Activation Protein which is a duplicate
molecule of DPP-4 (FAP-DPP-4 shows 88% homology at cDNA
level) is present at the tissue remodeling interface on hepatic
stellate cells (HSCs, ITO cells) which are thought to primarily
produce the accumulating extracellular matrix (ECM) proteins
(including collagens) in chronic liver diseases eventually leading to
the fibrosis and cirrhosis of the liver.[23]
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